Company Overview and News

Emerald Health Therapeutics Expands Strategic Investment in VANC

2018-04-17 globenewswire
VANCOUVER, British Columbia, April 17, 2018 (GLOBE NEWSWIRE) -- VANC Pharmaceuticals Inc. (“VANC”) announced today that it has entered into a supply and distribution agreement (“Distribution Agreement”) with an affiliate of Emerald Health Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) (“Emerald”), pursuant to which VANC was granted rights to sell and distribute certain proprietary endocannabinoid-supporting products in Canada to licensed pharmacies.
Upvote Downvote

TheBaron VII: Tough Market Movement Spells Opportunity

2018-03-28 seekingalpha
The overall portfolio had a weak month due mainly to one company's continued share price weakness, with slight moves downwards in most of the portfolio.
Upvote Downvote

BRIEF-Village Farms International Reschedules Q4 And Year End Financial Results Conf Call

2018-03-19 reuters
Upvote Downvote

TheBaron VI: Active February Brings New Strategy

2018-03-06 seekingalpha
As the portfolio grows I have begun to modify my investment criteria to initiate new holdings within low and medium yield companies to complement my high yield holdings.
Upvote Downvote

TheBaron Investing: Marijuana Collapses

2018-02-05 seekingalpha
The market has decided to cool on marijuana companies, which is appropriate but frustrating to see an undervalued company decline.
Upvote Downvote

Like Marijuana Post-Crash? You'll Love This Company

2018-02-05 seekingalpha
This is the second time I am writing about Village Farms International, due to the undervaluation that is still present in its price.
Upvote Downvote

Emerald Health: West Coast Cannabis Player With Biotech Focus

2018-02-05 seekingalpha
Our followers would have read our Weekly Cannabis Report in which we started tracking weekly performance of 11 cannabis companies, in addition to providing a weekly update on the latest news and developments in the sector. Starting today we are rolling out our initiating reports for the 11 names that we cover in order to offer deeper insights and analysis for our readers.
Upvote Downvote

Greenhouse growers take chance on cannabis in push for green

2018-02-01 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to:
Upvote Downvote

Village Farms International: Cannabis And Tomatoes

2018-01-29 seekingalpha
Village Farms recently made an 50/50 ownership agreement with Emerald Health Therapeutics to create Pure Sunfarms, an up-and-coming cannabis producer.
Upvote Downvote

TheBaron Investing: Good Start To The Year, 500 Follower Update

2018-01-11 seekingalpha
Due to capital constraints there have only been a couple smaller purchases as we continue to add positions to the portfolio.
Upvote Downvote

Canadian Cannabis Stocks: 2018 Outlook

2018-01-03 seekingalpha
Canadian cannabis stocks had a positive year in 2017 with the Let's Toke Business Marijuana Composite posting a return of.21.7% and the LTB Licensed Producer Index recording a return of.46.0%.
Upvote Downvote

Budding Marijuana Company In Canada

2017-12-13 seekingalpha
They have the facilities, and partner, to potentially become a major player in the North American market.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...